FreshRSS

🔒
❌ Acerca de FreshRSS
Hay nuevos artículos disponibles. Pincha para refrescar la página.
AnteayerTus fuentes RSS

Azithromycin use in labour to prevent sepsis among pregnant women undergoing vaginal delivery in Nigeria (AZIN-V): a study protocol for a hybrid type 2 effectiveness-implementation trial

Por: Afolabi · B. B. · Makwe · C. C. · Oluwole · E. O. · Obi-Jeff · C. · Mitchell · E. J. · Banke-Thomas · A. · Adeyemo · T. A. · Abioye · A. I. · Eboreime · E. A. · Saidu · A. D. · Okoro · U. A. · Akintan · P. · Osuagwu · C. S. · Chieme · C. F. · Lawanson · T. · Hossain · A. · Walker · K.
Introduction

Nigeria has the highest number of maternal deaths globally, and maternal peripartum sepsis is one of the leading causes of maternal mortality. A single oral dose of azithromycin (AZM; 2 g) is safe and effectively reduces 33%–60% of maternal sepsis during planned vaginal birth in low- and middle-income countries (LMICs). However, the clinical and cost-effectiveness of oral AZM during vaginal birth in Nigeria remains unknown in the context of poor antimicrobial stewardship practices, significant antimicrobial resistance and healthcare financing. Evidence is also lacking on the standard care for the prevention of maternal sepsis among pregnant women undergoing vaginal births in Nigeria. The AZIN-V trial is a hybrid type 2 effectiveness-implementation trial to determine the safety, clinical and cost-effectiveness of intrapartum oral AZM versus usual care in the prevention of peripartum maternal sepsis. The trial will also examine the impact of implementation strategies in enhancing adherence to the oral AZM protocol during planned vaginal births and identify effective strategies to improve adherence (fidelity) to the protocol in real-world LMIC settings.

Methods and analysis

This is a multicentre hybrid type 2 trial conducted in six Nigerian states: Ebonyi, Edo, Gombe, Kano, Kwara and Lagos. The study aims to simultaneously test the clinical and cost-effectiveness of AZM (clinical trial) and the impact of implementation strategies (implementation research) in Nigeria’s unique healthcare context. The clinical trial is a two-arm, cluster-randomised controlled trial conducted across 48 health facilities, randomly assigned (1:1) to either intrapartum administration of oral AZM (intervention group) or usual care—the current routine practice (control group). A total of 5040 study participants (2520 in each group) will be enrolled in the clinical trial. The implementation trial is a two-arm cluster non-randomised controlled trial conducted in 12 health facilities (1:1) allocated to either a bottom-up approach using the Plan-Do-Study-Act cycle or a usual top-down approach with a one-time training workshop and distribution of clinical guidelines, with both arms administering oral AZM during vaginal birth while assessing fidelity (primary outcome).

For the clinical trial, data will be analysed using intention-to-treat statistical methods. The cost-effectiveness outcome will be analysed using the Incremental Cost-Effectiveness Ratio. Implementation outcomes will be analysed using descriptive statistics and a thematic approach.

Ethics and dissemination

This study has been approved by the National Health Research Ethics Committee, Nigeria (NHREC/01/01/2007-30/09/2024), the ethics committees of the participating health institutions (Lagos University Teaching Hospital Research Ethics Committee: ADM/DSCST/HREC/APP/6325; University of Ilorin Teaching Hospital Health Research Ethics Committee: ERC/PAN/2025/03/0581; University of Benin Teaching Hospital Health Research Ethics Committee: ADM/E22/A/VOL. VII/483117141; Aminu Kano Teaching Hospital Research Ethics Committee: AKTH/MAC/SUB/12 A/P-3/VI/2509 and Irrua Specialist Teaching Hospital Research Ethics Committee: ISTH/HREC/20241507/605), the Ministries of Health of the six states and the National Agency for Food and Drug Administration and Control. Written informed consent will be obtained from all eligible study participants before enrolment. Results will be shared with communities and policy stakeholders and through peer-reviewed journals and will be presented at conferences.

Trial registration number

ISRCTN16415327.

Protocol for systematic review and multilevel meta-analysis comparing efficacy and safety of endoscopic versus open gluteal tendon repair

Por: Ramadanov · N. · Voss · M. · Lott · A. · Banke · I. J.
Background

Gluteal tendon tears—frequently dubbed the ‘rotator cuff tears of the hip’—are a common but often underdiagnosed cause of lateral hip pain and abductor dysfunction, especially in middle-aged to older women. While both open and endoscopic repair techniques are used, current literature suggests similar functional outcomes but higher complication rates following open repair. However, evidence is mainly derived from small retrospective case series, and no randomised trials exist. This systematic review and multilevel meta-analysis aims to compare the efficacy, safety and complication profiles of endoscopic versus open gluteal tendon repair.

Methods

A comprehensive literature search will be conducted across PubMed, Embase, CENTRAL and Epistemonikos without language or date restrictions. Eligible studies include randomised controlled trials and observational studies reporting on open or endoscopic gluteal tendon repair. Primary outcomes will include pain, functional scores and complication rates. Risk of bias will be assessed using the RoB 2 tool for RCTs and ROBINS-I for non-randomised studies. A three-level random-effects meta-analysis will be performed using inverse variance weighting and Hartung-Knapp adjustments. Heterogeneity will be quantified using the I² statistic.

Ethics and dissemination

Ethical approval is not required for this secondary analysis of published data. Results will be disseminated via peer-reviewed publication and conference presentations.

Timeline and review status

The review will commence immediately after acceptance of this study protocol in BMJ Open. The systematic review and multilevel meta-analysis will be conducted as efficiently as possible, with anticipated completion approximately 3–6 months after initiation.

PROSPERO registration number

CRD420251088765

Effect of vitamin D supplementation during pregnancy and lactation on the development of infants born to Tanzanian women living with HIV: a secondary analysis of a randomised controlled trial

Por: Shobanke · T. · Muhihi · A. · Perumal · N. · Ulenga · N. · Al-Beity · F. M. A. · Duggan · C. P. · Fawzi · W. W. · Manji · K. P. · Sudfeld · C. R.
Background

Infants born to pregnant women living with HIV (WLHIV) are at greater risk for morbidity and mortality and may also have poorer developmental outcomes as compared with infants who are not exposed to HIV. Nutrition interventions in pregnancy may affect developmental outcomes.

Objectives

This study evaluated the effect of maternal vitamin D supplementation on infant development outcomes.

Design

We conducted a secondary analysis of a randomised, triple-blind, placebo-controlled trial of maternal vitamin D supplementation from June 2015 to October 2019.

Setting

Antenatal care clinics in Dar es Salaam, Tanzania.

Participants

Pregnant WLHIV and their offspring.

Interventions

Daily 3000 IU vitamin D3 or placebo supplements taken during pregnancy and lactation.

Outcome measures

Infants were assessed for cognitive, language and motor development at 1 year of age with the Caregiver Reported Early Development Instruments (CREDI).

Results

A total of 2167 infants were eligible, and 1312 of them completed CREDI assessments at 1 year of age. Vitamin D supplementation had no effect on overall CREDI z-scores (standardised mean difference (SMD) 0.03, 95% CI –0.09, 0.15, p value 0.66). There was also no evidence of a difference between vitamin D and placebo groups in language (SMD 0.06, 95% CI –0.08, 0.21, p value 0.40), motor (SMD 0.02, 95% CI –0.09, 0.14, p value 0.69) or cognitive domain z-scores (SMD 0.05, 95% CI –0.08, 0.17, p 0.48).

Conclusions

Maternal vitamin D supplementation during pregnancy and lactation did not affect infant development outcomes.

Trial registration number

ClinicalTrials.gov identifier: NCT02305927.

❌